Works by Flinn, Ian

Results: 73
    1
    2

    MALT Lymphomas.

    Published in:
    2003
    By:
    • Malek, Sami;
    • Hatfield, Amy;
    • Flinn, Ian;
    • Malek, Sami N;
    • Hatfield, Amy J;
    • Flinn, Ian W
    Publication type:
    journal article
    3
    4
    5
    6

    Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy.

    Published in:
    EJHaem, 2024, v. 5, n. 5, p. 929, doi. 10.1002/jha2.1013
    By:
    • Lamanna, Nicole;
    • Tam, Constantine S.;
    • Woyach, Jennifer A.;
    • Alencar, Alvaro J.;
    • Palomba, M. Lia;
    • Zinzani, Pier Luigi;
    • Flinn, Ian W.;
    • Fakhri, Bita;
    • Cohen, Jonathon B.;
    • Kontos, Arrin;
    • Konig, Heiko;
    • Ruppert, Amy S.;
    • Chatterjee, Anindya;
    • Sizelove, Richard;
    • Compte, Livia;
    • Tsai, Donald E.;
    • Jurczak, Wojciech
    Publication type:
    Article
    7

    Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma.

    Published in:
    EJHaem, 2022, v. 3, n. 1, p. 139, doi. 10.1002/jha2.375
    By:
    • Ribrag, Vincent;
    • Chavez, Julio C.;
    • Boccomini, Carola;
    • Kaplan, Jason;
    • Chandler, Jason C.;
    • Santoro, Armando;
    • Corradini, Paolo;
    • Flinn, Ian W.;
    • Advani, Ranjana;
    • Cassier, Philippe A.;
    • Sangha, Randeep;
    • Kenkre, Vaishalee P.;
    • Isufi, Iris;
    • Uttamsingh, Shailaja;
    • Hagner, Patrick R.;
    • Gandhi, Anita K.;
    • Shen, Frank;
    • Michelliza, Sophie;
    • Haeske, Harald;
    • Hege, Kristen
    Publication type:
    Article
    8

    Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma.

    Published in:
    EJHaem, 2022, v. 3, n. 2, p. 394, doi. 10.1002/jha2.394
    By:
    • Nastoupil, Loretta J.;
    • Kuruvilla, John;
    • Chavez, Julio C.;
    • Bijou, Fontanet;
    • Witzig, Thomas E.;
    • Santoro, Armando;
    • Flinn, Ian W.;
    • Boccomini, Carola;
    • Kenkre, Vaishalee P.;
    • Corradini, Paolo;
    • Isufi, Iris;
    • Andorsky, David J.;
    • Klein, Leonard M.;
    • Greenwald, Daniel R.;
    • Sangha, Randeep;
    • Shen, Frank;
    • Hagner, Patrick;
    • Li, Yan;
    • Dobmeyer, Juergen;
    • Gong, Nian
    Publication type:
    Article
    9

    ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S378, doi. 10.1016/S2152-2650(21)01863-2
    By:
    • Cohen, Jonathon B.;
    • Shah, Nirav N.;
    • Alencar, Alvaro J.;
    • Gerson, James N.;
    • Patel, Manish R.;
    • Fahkri, Bita;
    • Jurczak, Wojciech;
    • Tan, Xuan N.;
    • Lewis, Katharine L.;
    • Fenske, Timothy S.;
    • Coombs, Catherine C.;
    • Flinn, Ian;
    • Lewis, David J.;
    • Gouill, Stephen Le;
    • Palomba, M Lia;
    • Woyach, Jennifer A.;
    • Pagel, John M.;
    • Lamanna, Nicole;
    • Barve, Minal A.;
    • Ghia, Paolo
    Publication type:
    Article
    10

    CLL-139: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S318, doi. 10.1016/S2152-2650(21)01751-1
    By:
    • Sharman, Jeff P.;
    • Egyed, Miklos;
    • Jurczak, Wojciech;
    • Skarbnik, Alan;
    • Pagel, John M.;
    • Flinn, Ian W.;
    • Kamdar, Manali;
    • Munir, Talha;
    • Walewska, Renata;
    • Corbett, Gillian;
    • Fogliatto, Laura Maria;
    • Herishanu, Yair;
    • Banerji, Versha;
    • Coutre, Steven;
    • Follows, George;
    • Walker, Patricia;
    • Karlsson, Karin;
    • Ghia, Paolo;
    • Janssens, Ann;
    • Cymbalista, Florence
    Publication type:
    Article
    11

    Poster: ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S241, doi. 10.1016/S2152-2650(21)01513-5
    By:
    • Cohen, Jonathon B.;
    • Shah, Nirav N.;
    • Alencar, Alvaro J.;
    • Gerson, James N.;
    • Patel, Manish R.;
    • Fahkri, Bita;
    • Jurczak, Wojciech;
    • Tan, Xuan N.;
    • Lewis, Katharine L.;
    • Fenske, Timothy S.;
    • Coombs, Catherine C.;
    • Flinn, Ian;
    • Lewis, David J.;
    • Le Gouill, Stephen;
    • Palomba, M. Lia;
    • Woyach, Jennifer A.;
    • Pagel, John M.;
    • Lamanna, Nicole;
    • Barve, Minal A.;
    • Ghia, Paolo
    Publication type:
    Article
    12

    Poster: CLL-139: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S220, doi. 10.1016/S2152-2650(21)01390-2
    By:
    • Sharman, Jeff P.;
    • Egyed, Miklos;
    • Jurczak, Wojciech;
    • Skarbnik, Alan;
    • Pagel, John M.;
    • Flinn, Ian W.;
    • Kamdar, Manali;
    • Munir, Talha;
    • Walewska, Renata;
    • Corbett, Gillian;
    • Fogliatto, Laura Maria;
    • Yair Herishanu;
    • Banerji, Versha;
    • Coutre, Steven;
    • Follows, George;
    • Walker, Patricia;
    • Karlsson, Karin;
    • Ghia, Paolo;
    • Janssens, Ann;
    • Cymbalista, Florence
    Publication type:
    Article
    13

    Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S317, doi. 10.1016/j.clml.2019.07.293
    By:
    • Phillips, Tycel;
    • Smith, Stephen D.;
    • Jurczak, Wojciech;
    • Robak, Tadeusz;
    • Stevens, Don A.;
    • Farber, Charles M.;
    • Pagel, John M.;
    • Maddocks, Kami;
    • Flinn, Ian;
    • Jedrzejczak, Wieslaw W.;
    • Goy, Andre;
    • Zinzani, Pier Luigi;
    • Zaucha, Jan;
    • Coleman, Morton;
    • Chen, Tianling;
    • Lee, Sun Ku;
    • Liang, Wei;
    • Seto, Anna;
    • Wang, Michael
    Publication type:
    Article
    14

    An Improved Benefit-Risk Profile of Duvelisib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received ≥2 Prior Therapies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S276, doi. 10.1016/j.clml.2019.07.209
    By:
    • Davids, Matthew;
    • Hillmen, Peter;
    • Montillo, Marco;
    • Delgado, Julio;
    • Kuss, Bryone;
    • Tam, Constantine;
    • Jäger, Ulrich;
    • Ghia, Paolo;
    • Stilgenbauer, Stephan;
    • Cymbalista, Florence;
    • Lustgarten, Stephanie;
    • Weaver, David;
    • Youssoufian, Hagop;
    • Flinn, Ian
    Publication type:
    Article
    15

    Patterns of Duvelisib-Induced Lymphocytosis in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including Those with High-Risk Factors Treated in the DUO Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S275, doi. 10.1016/j.clml.2019.07.208
    By:
    • Barrientos, Jacqueline;
    • Flinn, Ian;
    • Davids, Matthew;
    • Cashen, Amanda;
    • Chiorazzi, Nicholas;
    • Chen, Shih-Shih;
    • Hidy, Samantha;
    • Pachter, Jonathan;
    • Lustgarten, Stephanie;
    • Weaver, David;
    • Brown, Jennifer R.
    Publication type:
    Article
    16

    Effect of Dose Modifications on Response to Duvelisib in Patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S273, doi. 10.1016/j.clml.2019.07.204
    By:
    • Flinn, Ian;
    • Montillo, Marco;
    • Illés, Árpád;
    • Etienne, Gabriel;
    • Delgado, Julio;
    • Kuss, Bryone;
    • Tam, Constantine;
    • Offner, Fritz;
    • Bosch, Francesc;
    • Davids, Matthew;
    • Jäger, Ulrich;
    • Ghia, Paolo;
    • Cymbalista, Florence;
    • Weaver, David;
    • Lustgarten, Stephanie;
    • Youssoufian, Hagop;
    • Stilgenbauer, Stephan;
    • Lamanna, Nicole
    Publication type:
    Article
    17
    18

    Managing Cytokine Release Syndrome and Neurotoxicity with Step-Up Dosing of Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S247, doi. 10.1016/j.clml.2019.07.151
    By:
    • Bartlett, Nancy L.;
    • Sehn, Laurie H.;
    • Assouline, Sarit;
    • Bosch, Francesc;
    • Diefenbach, Catherine M.;
    • Flinn, Ian;
    • Hong, Jung Yong;
    • Kim, Wonseog S.;
    • Matasar, Matthew;
    • Nastoupil, Loretta;
    • Schuster, Stephen J.;
    • Shadman, Mazyar;
    • Yoon, Sung-Soo;
    • Bender, Brendan;
    • Chu, Wayne;
    • Hernandez, Genevive;
    • Kwan, Antonia;
    • McCall, Bruce;
    • Sison, Iris;
    • Wang, Cunlin
    Publication type:
    Article
    19

    Tumor Debulking and Reduction in Risk of Tumor Lysis Syndrome with Single-Agent Ibrutinib.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S304, doi. 10.1016/j.clml.2017.07.100
    By:
    • Kipps, Thomas J.;
    • Wierda, William G.;
    • Byrd, John C.;
    • O’Brien, Susan;
    • Coutre, Steven;
    • Barr, Paul M.;
    • Furman, Richard R.;
    • Burger, Jan A.;
    • Stevens, Don;
    • Sharman, Jeff;
    • Ghia, Paolo;
    • Flinn, Ian;
    • Zhou, Cathy;
    • Ninomoto, Joi;
    • James, Danelle F.;
    • Tam, Constantine
    Publication type:
    Article
    20
    21
    22

    Brief-Duration Rituximab/Chemotherapy Followed by Maintenance Rituximab in Patients With Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy: A Phase II Trial of the Sarah Cannon Oncology Research Consortium.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 1, p. 44, doi. 10.3816/CLML.2010.n.004
    By:
    • Hainsworth, John D.;
    • Flinn, Ian W.;
    • Spigel, David R.;
    • Clark, Bobby L.;
    • Griner, Paula L.;
    • Vazquez, Elizabeth R.;
    • Doss, Habib H.;
    • Shipley, Dianna;
    • Franco, Luis A.;
    • Burris, III, Howard A.;
    • Greco, F. Anthony
    Publication type:
    Article
    23
    24
    25
    26
    27
    28

    Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111 In)/Yttrium 90 (90 Y) Ibritumomab Tiuxetan (Zevalin ®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.

    Published in:
    Cancers, 2021, v. 13, n. 11, p. 2828, doi. 10.3390/cancers13112828
    By:
    • Wahl, Richard L.;
    • Frey, Eric C.;
    • Jacene, Heather A.;
    • Kahl, Brad S.;
    • Piantadosi, Steven;
    • Bianco, Jesus A.;
    • Hammes, Richard J.;
    • Jung, Miah;
    • Kasecamp, Wayne;
    • He, Bin;
    • Sgouros, George;
    • Flinn, Ian W.;
    • Swinnen, Lode J.
    Publication type:
    Article
    29
    30
    31
    32
    33

    The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma.

    Published in:
    British Journal of Haematology, 2020, v. 189, n. 4, p. 650, doi. 10.1111/bjh.16424
    By:
    • Fowler, Nathan H.;
    • Nastoupil, Loretta;
    • De Vos, Sven;
    • Knapp, Mark;
    • Flinn, Ian W.;
    • Chen, Robert;
    • Advani, Ranjana H.;
    • Bhatia, Sumeet;
    • Martin, Peter;
    • Mena, Raul;
    • Davis, Richard Eric;
    • Neelapu, Sattva S.;
    • Eckert, Karl;
    • Ping, Jerry;
    • Co, Melannie;
    • Beaupre, Darrin M.;
    • Neuenburg, Jutta K.;
    • Palomba, M. Lia
    Publication type:
    Article
    34

    Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single‐agent ibrutinib in patients with chronic lymphocytic leukaemia.

    Published in:
    British Journal of Haematology, 2019, v. 186, n. 1, p. 184, doi. 10.1111/bjh.15791
    By:
    • Wierda, William G.;
    • Byrd, John C.;
    • O'Brien, Susan;
    • Coutre, Steven;
    • Barr, Paul M.;
    • Furman, Richard R.;
    • Kipps, Thomas J.;
    • Burger, Jan A.;
    • Stevens, Don A.;
    • Sharman, Jeff;
    • Ghia, Paolo;
    • Flinn, Ian W.;
    • Zhou, Cathy;
    • Ninomoto, Joi;
    • James, Danelle F.;
    • Tam, Constantine S.
    Publication type:
    Article
    35
    36
    37
    38

    Real-world clinical experience in the Connect<sup>®</sup> chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres.

    Published in:
    British Journal of Haematology, 2016, v. 175, n. 5, p. 892, doi. 10.1111/bjh.14332
    By:
    • Mato, Anthony;
    • Nabhan, Chadi;
    • Kay, Neil E.;
    • Weiss, Mark A.;
    • Lamanna, Nicole;
    • Kipps, Thomas J.;
    • Grinblatt, David L.;
    • Flinn, Ian W.;
    • Kozloff, Mark F.;
    • Flowers, Christopher R.;
    • Farber, Charles M.;
    • Kiselev, Pavel;
    • Swern, Arlene S.;
    • Sullivan, Kristen;
    • Flick, E. Dawn;
    • Sharman, Jeff P.
    Publication type:
    Article
    39
    40

    A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

    Published in:
    British Journal of Haematology, 2014, v. 167, n. 4, p. 466, doi. 10.1111/bjh.13061
    By:
    • Awan, Farrukh T.;
    • Hillmen, Peter;
    • Hellmann, Andrzej;
    • Robak, Tadeusz;
    • Hughes, Steven G.;
    • Trone, Denise;
    • Shannon, Megan;
    • Flinn, Ian W.;
    • Byrd, John C.
    Publication type:
    Article
    41
    42
    43

    Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study.

    Published in:
    Acta Haematologica Polonica, 2022, v. 53, n. A, p. 42
    By:
    • Jurczak, Wojciech;
    • Wang, Michael;
    • Shah, Nirav;
    • Alencar, Alvaro;
    • Gerson, James;
    • Patel, Manish;
    • Fakhri, Bita;
    • Xuan Tan;
    • Lewis, Katharine;
    • Flinn, Ian;
    • Lewis, Davud;
    • Le Gouill, Steven;
    • Palomba, Lia;
    • Woyach, Jennifer;
    • Pagel, John;
    • Lamanna, Nicole;
    • Cohen, Johnathon;
    • Barve, Minal;
    • Ghia, Paolo;
    • Eyre, Toby
    Publication type:
    Article
    44

    Primary results from the double-blind, placebo-controlled, phase 3 SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).

    Published in:
    Acta Haematologica Polonica, 2022, v. 53, n. A, p. 42
    By:
    • Jurczak, Wojciech;
    • Gouill, Steven Le;
    • Jerkeman, Mats;
    • Trotman, Judith;
    • Zinzani, Pier Luigi;
    • Belada, David;
    • Boccomini, Carola;
    • Flinn, Ian W.;
    • Giri, Pratyush;
    • Goy, Andre;
    • Hamlin, Paul A.;
    • Hermine, Olivier;
    • Hernández-Rivas, José-ángel;
    • Xiaonan Hong;
    • Seok Jin Kim;
    • Lewis, David;
    • Yuko Mishima;
    • Özcan, Muhit;
    • Perini, Guilherme Fleury;
    • Pocock, Christopher
    Publication type:
    Article
    45

    SEQUOIA: results of a phase 3 randomized study of Zanubrutinib versus Bendamustine + Rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

    Published in:
    Acta Haematologica Polonica, 2022, v. 53, n. A, p. 32
    By:
    • Robak, Tadeusz;
    • Giannopoulos, Krzysztof;
    • Jurczak, Wojciech;
    • Šimkovič, Martin;
    • Shadman, Mazyar;
    • Österborg, Anders;
    • Laurenti, Luca;
    • Walker, Patricia;
    • Opat, Stephen;
    • Chan, Henry;
    • Ciepluch, Hanna;
    • Greil, Richard;
    • Tani, Monica;
    • Trněný, Marek;
    • Brander, Danielle M.;
    • Flinn, Ian W.;
    • Grosicki, Sebastian;
    • Verner, Emma;
    • Kahl, Brad S.;
    • Ghia, Paolo
    Publication type:
    Article
    46
    47
    48
    49
    50